Axsome Therapeutics (AXSM) EBT (2015 - 2026)
Axsome Therapeutics (AXSM) reported EBT of -$64.5 million for Q1 2026, down 8.63% on a YoY basis from -$70.6 million in Q1 2025, and down 129.45% sequentially from -$28.1 million in Q4 2025.
Axsome Therapeutics (AXSM) EBT (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of EBT data on file, last reported at -$64.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 8.63% year-over-year to -$64.5 million; the trailing twelve-month figure through Mar 2026 stood at -$188.8 million (up 32.12% YoY), and the FY2025 full-year result was -$183.7 million, up 36.02% from the prior year.
- EBT declined to -$64.5 million in Q1 2026, from -$28.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$8.6 million in Q1 2023 to a low of -$99.0 million in Q4 2023.
- A 5-year average of -$56.5 million and a median of -$61.2 million in 2022 frame the typical range for EBT.
- Across the five-year window, EBT surged 81.04% in 2022 and slumped 691.35% in 2024, its largest moves.
- Tracing AXSM's EBT over 5 years: stood at -$61.2 million in 2022, then tumbled by 61.62% to -$99.0 million in 2023, then advanced by 24.4% to -$74.8 million in 2024, then jumped by 62.41% to -$28.1 million in 2025, then sank by 129.45% to -$64.5 million in 2026.
- Business Quant data shows AXSM's EBT at -$64.5 million in Q1 2026, -$28.1 million in Q4 2025, and -$47.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -64.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.54 Mn |
| Dec 31, 2025 | -28.13 Mn |
| Sep 30, 2025 | -47.23 Mn |
| Jun 30, 2025 | -48.93 Mn |
| Mar 31, 2025 | -59.41 Mn |
| Dec 31, 2024 | -74.83 Mn |
| Sep 30, 2024 | -64.60 Mn |
| Jun 30, 2024 | -79.35 Mn |
| Mar 31, 2024 | -68.36 Mn |
| Dec 31, 2023 | -98.98 Mn |
| Sep 30, 2023 | -62.88 Mn |
| Jun 30, 2023 | -67.79 Mn |
| Mar 31, 2023 | -8.64 Mn |
| Dec 31, 2022 | -61.24 Mn |
| Sep 30, 2022 | -44.82 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -39.63 Mn |
| Dec 31, 2021 | -35.12 Mn |
| Sep 30, 2021 | -219.49 Mn |
| Jun 30, 2021 | -218.58 Mn |